NCT06888648View on ClinicalTrials.gov

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2028

Conditions
Pancreatic Cancer MetastaticPancreatic Cancer Non-resectable
Interventions
BIOLOGICAL

individualized anti-tumor new antigen iNeo-Vac-R01 injection

The individualized anti-tumor new antigen iNeo-Vac-R01 injection was commissioned by Hangzhou Nuanjin Biotechnology Co., Ltd., and all patients were admitted into the therapeutic intervention group. According to the results of previous non-clinical studies, the individualized mRNA injection of 100 μ g was a tolerable dose.

DRUG

mFOLFIRINOX Treatment Regimen

continuous intravenous infusion of fluorouracil 2400mg / m², for 46 hours, leucovorin 400mg / m², irinotecan 135mg / m², and oxaliplatin 68mg / m², every 2 weeks

DRUG

Sintilimab injection

Sintilimab Injection, 200mg, intravenous infusion, every 3 weeks

Trial Locations (1)

31000

First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou

All Listed Sponsors
collaborator

Hangzhou Neoantigen Therapeutics Co., Ltd.

INDUSTRY

lead

Zhejiang University

OTHER